We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Abbott (ABT - Free Report) closed at $101.82 in the latest trading session, marking a +2.23% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow gained 0.38%, while the tech-heavy Nasdaq lost 0.44%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 2.31% in the past month. In that same time, the Medical sector gained 0.04%, while the S&P 500 gained 2.36%.
Market participants will be closely following the financial results of Abbott in its upcoming release. The company plans to announce its earnings on October 21, 2026. The company's upcoming EPS is projected at $1.42, signifying a 9.23% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.91 billion, up 13.52% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott is currently a Zacks Rank #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 18.04. Its industry sports an average Forward P/E of 19.61, so one might conclude that Abbott is trading at a discount comparatively.
One should further note that ABT currently holds a PEG ratio of 1.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry had an average PEG ratio of 1.74 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Abbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT - Free Report) closed at $101.82 in the latest trading session, marking a +2.23% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow gained 0.38%, while the tech-heavy Nasdaq lost 0.44%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 2.31% in the past month. In that same time, the Medical sector gained 0.04%, while the S&P 500 gained 2.36%.
Market participants will be closely following the financial results of Abbott in its upcoming release. The company plans to announce its earnings on October 21, 2026. The company's upcoming EPS is projected at $1.42, signifying a 9.23% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.91 billion, up 13.52% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott is currently a Zacks Rank #2 (Buy).
With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 18.04. Its industry sports an average Forward P/E of 19.61, so one might conclude that Abbott is trading at a discount comparatively.
One should further note that ABT currently holds a PEG ratio of 1.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry had an average PEG ratio of 1.74 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.